Meeder Asset Management Inc. grew its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 28.3% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,923 shares of the biotechnology company’s stock after buying an additional 1,308 shares during the quarter. Meeder Asset Management Inc.’s holdings in Repligen were worth $350,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in RGEN. Bank of New York Mellon Corp grew its stake in shares of Repligen by 3.4% during the third quarter. Bank of New York Mellon Corp now owns 516,025 shares of the biotechnology company’s stock valued at $28,620,000 after buying an additional 17,176 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Repligen by 5.6% during the third quarter. Dimensional Fund Advisors LP now owns 1,073,887 shares of the biotechnology company’s stock valued at $59,556,000 after buying an additional 57,067 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Repligen during the third quarter valued at approximately $543,000. Pacer Advisors Inc. bought a new position in shares of Repligen during the third quarter valued at approximately $116,000. Finally, MetLife Investment Advisors LLC grew its stake in shares of Repligen by 55.5% during the third quarter. MetLife Investment Advisors LLC now owns 27,358 shares of the biotechnology company’s stock valued at $1,517,000 after buying an additional 9,760 shares during the last quarter. 91.18% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ RGEN opened at $54.74 on Tuesday. The company has a market capitalization of $2.41 billion, a P/E ratio of 74.99, a PEG ratio of 3.77 and a beta of 1.08. Repligen Co. has a 52-week low of $36.41 and a 52-week high of $70.50.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 21st. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.21. The firm had revenue of $51.90 million during the quarter, compared to analyst estimates of $50.27 million. Repligen had a return on equity of 5.51% and a net margin of 8.56%. Repligen’s quarterly revenue was up 24.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.20 earnings per share. As a group, research analysts expect that Repligen Co. will post 0.83 EPS for the current fiscal year.

A number of research analysts have recently commented on RGEN shares. ValuEngine cut Repligen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 4th. BidaskClub cut Repligen from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. Finally, Zacks Investment Research cut Repligen from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $59.20.

In related news, CEO Anthony Hunt sold 7,475 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The stock was sold at an average price of $59.01, for a total value of $441,099.75. Following the completion of the sale, the chief executive officer now owns 250,132 shares in the company, valued at $14,760,289.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Ralf Kuriyel sold 2,240 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $58.53, for a total value of $131,107.20. Following the completion of the sale, the vice president now owns 21,043 shares of the company’s stock, valued at approximately $1,231,646.79. The disclosure for this sale can be found here. Insiders sold 48,437 shares of company stock valued at $2,855,032 in the last quarter. 1.40% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/meeder-asset-management-inc-has-350000-stake-in-repligen-co-rgen/2982045.html.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Further Reading: What is a Candlestick Chart?

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.